Please use this identifier to cite or link to this item:
Title: Vildagliptin induces β-Cell neogenesis and Improves the lipid profile in a later phase of type 1 diabetes.
Authors: Miranda, Pedro Henrique de Amorim
Monteiro, Otávio Montovanelli
Rossoni Júnior, Joamyr Victor
Silva, Marcelo Eustáquio
Lima, Wanderson Geraldo de
Costa, Daniela Caldeira
Keywords: β-cells
Lipid profile
Issue Date: 2015
Citation: MIRANDA, P. H. de A. et al. Vildagliptin induces β-Cell neogenesis and Improves the lipid profile in a later phase of type 1 diabetes. Current Pharmaceutical Biotechnology, v. 16, p. 60-65, 2015. Disponível em: <>. Acesso em: 21 mar. 2017.
Abstract: Recently, the inhibitor dipeptidyl peptidase-4 has been reported to be beneficial in the treatment of type 1 diabetes mellitus. For the first time, this study evaluates the effect of vildagliptin on β -cell neogenesis and lipid homeostasis in a later phase of type 1 diabetes. In Fischer rats, diabetes was induced with alloxan. After confirmation of diabetic status, the animals received no treatment for 30 days to establish a late phase of the disease these animals. After this period, the animals were treated with vildagliptin via gavage for 30 consecutive days. Fasting blood glucose, serum insulin, lipid profile and pancreatic histology were evaluated. Treatment with vildagliptin increased serum levels of insulin, improved beta cell function and improved the lipid profile. Histological analyses revealed that this treatment increased the populations of pancreatic β-cells in the diabetic animals. The treatment was effective in improving the mass and function of β-cells and contributed to lipid homeostasis, in an experimental model of type 1 diabetes.
ISSN: 1873-4316
Appears in Collections:DEALI - Artigos publicados em periódicos

Files in This Item:
File Description SizeFormat 
  Restricted Access
1,2 MBAdobe PDFView/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.